Vodafone Share News (VOD)

The Chief Financial Officer of drug maker AstraZeneca has shown his faith in the group following a setback on Thursday, which saw an advisory committee to the US Food and Drug Association vote against the accelerated approval of its ovarian cancer treatment. Marc Dunoyer, who joined the company in June last year, purchased 20,000 shares at 4,340p each in a deal worth £868,000. The FTSE 100 group said the committee had decided in an 11-2 vote that there was not enough evidence to support an accelerated approval for the use of olaparib as a maintenance treatment for women with a specific type of ovarian cancer. The recommendation of the Oncologic Drugs Advisory Committee, which provides the FDA with independent expert advice and recommendations, influences the final decision on approval of olaparib's use in patients with ovarian cancer who have the BRCA mutation and who are in complete or partial response to a platinum-based form of chemotherapy. AstraZeneca filed the US regulatory submission for olaparib in February 2014 and was granted priority review status for the new drug application (NDA) by the FDA in April based on data that showed the drug met its primary endpoint of progression-free survival in a specific type of the disease. The group admitted its was "disappointed" with the recommendation, saying it "strongly believe[s] that olaparib has the potential to provide patients with relapsed BRCA-mutated ovarian cancer and their doctors with a much-needed treatment option". Top Director BuysAstraZeneca (AZN) Director name: Mr Marc DunoyerAmount purchased: 20,000 @ 4,340.00p Value: £868,000El Oro Ltd (ELX) Director name: Mr C. Robin W. ParishAmount purchased: 70,500 @ 70.00p Value: £49,350600 Group (SIXH) Director name: Mr Nigel RogersAmount purchased: 139,780 @ 22.75p Value: £31,800Sound Oil (SOU) Director name: Mr James ParsonsAmount purchased: 257,009 @ 10.70p Value: £27,500Intercede Group (IGP) Director name: Mr Richard Arthur ParrisAmount purchased: 12,025 @ 195.00p Value: £23,449Development Securities (DSC) Director name: Mr Marcus Shepherd Amount purchased: 10,000 @ 217.00p Value: £21,700Vodafone Group (VOD) Director name: Mr Nicholas C E LandAmount purchased: 10,000 @ 190.44p Value: £19,044Goldenport Holdings Inc. (DI) (GPRT) Director name: Mr Alexis StephanouAmount purchased: 5,000 @ 352.00p Value: £17,6003i Group (III) Director name: Mrs Julia WilsonAmount purchased: 3,005 @ 393.08p Value: £11,8123i Group (III) Director name: Mrs Julia WilsonAmount purchased: 3,003 @ 393.28p Value: £11,810Top Director SellsBabcock International Group (BAB) Director name: Mr Peter L RogersAmount sold: 250,000 @ 1,151.25p Value: £2,878,125Babcock International Group (BAB) Director name: Mr Peter L RogersAmount sold: 76,620 @ 1,148.70p Value: £880,134Babcock International Group (BAB) Director name: Mr John DaviesAmount sold: 54,638 @ 1,148.70p Value: £627,627Babcock International Group (BAB) Director name: Mr William (Bill) TameAmount sold: 38,434 @ 1,148.70p Value: £441,491Babcock International Group (BAB) Director name: Mr Kevin ThomasAmount sold: 32,445 @ 1,148.70p Value: £372,696Babcock International Group (BAB) Director name: Mr Archie BethelAmount sold: 32,445 @ 1,148.70p Value: £372,696Babcock International Group (BAB) Director name: Mr Kevin ThomasAmount sold: 14,000 @ 1,146.32p Value: £160,485Man Group (EMG) Director name: Mr Jonathan SorrellAmount sold: 47,173 @ 101.16p Value: £47,720NR